Quarterly report · Q3
4544.TEDINET S100Q5GN
Period2022-04-01 → 2022-12-31
Filed2023-02-10
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 49
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥201.0bn | 2022-04-01 → 2022-12-31 | Cons. | Net sales |
| Revenue | ¥272.9bn | 2021-04-01 → 2022-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥197.9bn | 2021-04-01 → 2021-12-31 | Cons. | Net sales |
| Operating income | ¥23.6bn | 2022-04-01 → 2022-12-31 | Cons. | Operating income |
| Operating income | ¥36.2bn | 2021-04-01 → 2021-12-31 | Cons. | Operating income |
| Ordinary income | ¥23.2bn | 2022-04-01 → 2022-12-31 | Cons. | Ordinary income |
| Ordinary income | ¥47.4bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥35.5bn | 2021-04-01 → 2021-12-31 | Cons. | Ordinary income |
| Profit before tax | ¥25.8bn | 2022-04-01 → 2022-12-31 | Cons. | Income before income taxes |
| Profit before tax | ¥33.7bn | 2021-04-01 → 2021-12-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥18.8bn | 2022-04-01 → 2022-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥29.6bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥25.5bn | 2021-04-01 → 2021-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥18.8bn | 2022-04-01 → 2022-12-31 | Cons. | Profit loss |
| Net income | ¥25.5bn | 2021-04-01 → 2021-12-31 | Cons. | Profit loss |
| Total assets | ¥280.3bn | at 2022-12-31 | Cons. | Assets |
| Total assets | ¥286.6bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥277.0bn | at 2021-12-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥127.2bn | at 2022-12-31 | Cons. | Liabilities |
| Total liabilities | ¥146.4bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥153.2bn | at 2022-12-31 | Cons. | Net assets |
| Net assets / equity | ¥140.2bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥133.6bn | at 2021-12-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥30.5bn | at 2022-12-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥46.5bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥30.5bn | at 2022-12-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥46.5bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥46.2bn | at 2021-12-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥43.0bn | at 2021-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥19.2bn | 2022-04-01 → 2022-12-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥55.2bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥38.4bn | 2021-04-01 → 2021-12-31 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥24.9bn | 2022-04-01 → 2022-12-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥30.9bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥19.2bn | 2021-04-01 → 2021-12-31 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥10.9bn | 2022-04-01 → 2022-12-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥21.7bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥16.1bn | 2021-04-01 → 2021-12-31 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥330.26 | 2022-04-01 → 2022-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥56.84 | 2022-10-01 → 2022-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥519.55 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥447.68 | 2021-04-01 → 2021-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥105.45 | 2021-10-01 → 2021-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥330.22 | 2022-04-01 → 2022-12-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥519.42 | 2021-04-01 → 2022-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥447.55 | 2021-04-01 → 2021-12-31 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 54.6% | at 2022-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 48.9% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 48.2% | at 2021-12-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 38
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-12-31 | −¥6.2bn |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-12-31 | −¥6.2bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-12-31 | −¥3.3bn |
| jpcrp040300-q3r_E00967-000Clinical Lab Testing Businessreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥124.9bn |
| jpcrp040300-q3r_E00967-000Clinical Lab Testing Businessreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥124.7bn |
| jpcrp040300-q3r_E00967-000Clinical Lab Testing Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥212m |
| jpcrp040300-q3r_E00967-000Clinical Lab Testing Businessreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥2.7bn |
| jpcrp040300-q3r_E00967-000In Vitro Diagnostics Businessreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥61.6bn |
| jpcrp040300-q3r_E00967-000In Vitro Diagnostics Businessreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥55.6bn |
| jpcrp040300-q3r_E00967-000In Vitro Diagnostics Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥5.9bn |
| jpcrp040300-q3r_E00967-000In Vitro Diagnostics Businessreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥23.4bn |
| jpcrp040300-q3r_E00967-000Sterilization And Related Servicesreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥20.7bn |
| jpcrp040300-q3r_E00967-000Sterilization And Related Servicesreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥20.6bn |
| jpcrp040300-q3r_E00967-000Sterilization And Related Servicesreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥15m |
| jpcrp040300-q3r_E00967-000Sterilization And Related Servicesreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥825m |
| —segment total | revenue | 2022-04-01 → 2022-12-31 | ¥207.1bn |
| —segment total | revenue external | 2022-04-01 → 2022-12-31 | ¥201.0bn |
| —segment total | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥6.2bn |
| —segment total | segment profit | 2022-04-01 → 2022-12-31 | ¥26.9bn |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2021-12-31 | −¥7.2bn |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2021-12-31 | −¥7.2bn |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2021-12-31 | −¥775m |
| jpcrp040300-q3r_E00967-000Clinical Lab Testing Businessreportable segment | revenue | 2021-04-01 → 2021-12-31 | ¥131.2bn |
| jpcrp040300-q3r_E00967-000Clinical Lab Testing Businessreportable segment | revenue external | 2021-04-01 → 2021-12-31 | ¥131.0bn |
| jpcrp040300-q3r_E00967-000Clinical Lab Testing Businessreportable segment | revenue intersegment | 2021-04-01 → 2021-12-31 | ¥216m |
| jpcrp040300-q3r_E00967-000Clinical Lab Testing Businessreportable segment | segment profit | 2021-04-01 → 2021-12-31 | ¥17.7bn |
| jpcrp040300-q3r_E00967-000In Vitro Diagnostics Businessreportable segment | revenue | 2021-04-01 → 2021-12-31 | ¥52.1bn |
| jpcrp040300-q3r_E00967-000In Vitro Diagnostics Businessreportable segment | revenue external | 2021-04-01 → 2021-12-31 | ¥45.2bn |
| jpcrp040300-q3r_E00967-000In Vitro Diagnostics Businessreportable segment | revenue intersegment | 2021-04-01 → 2021-12-31 | ¥7.0bn |
| jpcrp040300-q3r_E00967-000In Vitro Diagnostics Businessreportable segment | segment profit | 2021-04-01 → 2021-12-31 | ¥17.8bn |
| jpcrp040300-q3r_E00967-000Sterilization And Related Servicesreportable segment | revenue | 2021-04-01 → 2021-12-31 | ¥21.8bn |
| jpcrp040300-q3r_E00967-000Sterilization And Related Servicesreportable segment | revenue external | 2021-04-01 → 2021-12-31 | ¥21.7bn |
| jpcrp040300-q3r_E00967-000Sterilization And Related Servicesreportable segment | revenue intersegment | 2021-04-01 → 2021-12-31 | ¥15m |
| jpcrp040300-q3r_E00967-000Sterilization And Related Servicesreportable segment | segment profit | 2021-04-01 → 2021-12-31 | ¥1.4bn |
| —segment total | revenue | 2021-04-01 → 2021-12-31 | ¥205.1bn |
| —segment total | revenue external | 2021-04-01 → 2021-12-31 | ¥197.9bn |
| —segment total | revenue intersegment | 2021-04-01 → 2021-12-31 | ¥7.2bn |
| —segment total | segment profit | 2021-04-01 → 2021-12-31 | ¥36.9bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 479
| Item | Context | Value | Unit |
|---|---|---|---|
| Fund code | FilingDateInstant | － | |
| Security code | FilingDateInstant | 45440 | |
| Filer name in japanese | FilingDateInstant | Original text (Japanese)H.U.グループホールディングス株式会社 | |
| Filer name in english | FilingDateInstant | H.U. Group Holdings, Inc. | |
| Fund name in japanese | FilingDateInstant | － | |
| Fund name in english | FilingDateInstant | － | |
| Cabinet office ordinance | FilingDateInstant | Original text (Japanese)企業内容等の開示に関する内閣府令 | |
| Document type | FilingDateInstant | Original text (Japanese)第四号の三様式 | |
| Accounting standards | FilingDateInstant | Japan GAAP | |
| Whether consolidated financial statements are prepared | FilingDateInstant | true | |
| Industry code when consolidated financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | CTE | |
| Industry code when financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | － | |
| Current fiscal year start date | FilingDateInstant | 2022-04-01 | |
| Current period end date | FilingDateInstant | 2022-12-31 | |
| Type of current period | FilingDateInstant | Q3 | |
| Current fiscal year end date | FilingDateInstant | 2023-03-31 | |
| Previous fiscal year start date | FilingDateInstant | 2021-04-01 | |
| Comparative period end date | FilingDateInstant | 2021-12-31 | |
| Previous fiscal year end date | FilingDateInstant | 2022-03-31 | |
| Next fiscal year start date | FilingDateInstant | － | |
| End date of quarterly or semi annual period of next fiscal year | FilingDateInstant | － | |
| Amendment flag | FilingDateInstant | false | |
| Identification of document subject to amendment | FilingDateInstant | － | |
| Report amendment flag | FilingDateInstant | false | |
| Xbrl amendment flag | FilingDateInstant | false | |
| Business results of group (text) | FilingDateInstant | Text · Plus | |
| Description of business (text) | FilingDateInstant | Text · Plus | |
| Business risks (text) | FilingDateInstant | Text · Plus | |
| Management analysis of financial position operating results and cash flows (text) | FilingDateInstant | Text · Plus | |
| Basic policy regarding control of company (text) | FilingDateInstant | Text · Plus | |
| Critical contracts for operation (text) | FilingDateInstant | Text · Plus | |
| Total number of shares (text) | FilingDateInstant | Text · Plus | |
| Issued shares total number of shares etc (text) | FilingDateInstant | Text · Plus | |
| Class issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)普通株式 | |
| Name of financial instruments exchange on which securities are listed or authorized financial instruments business association to which securities are registered | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)東京証券取引所プライム市場 | |
| Description issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)単元株式数100株 | |
| Details of employee share option program (text) | FilingDateInstant | Text · Plus | |
| Other information on share acquisition rights (text) | FilingDateInstant | Text · Plus | |
| Exercises etc of moving strike convertible bonds etc (text) | FilingDateInstant | Text · Plus | |
| Changes in number of issued shares stated capital etc (text) | FilingDateInstant | Text · Plus | |
| Major shareholders (text) | FilingDateInstant | Text · Plus | |
| Issued shares voting rights (text) | FilingDateInstant | Text · Plus | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithNoVotingRightsMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithFullVotingRightsTreasurySharesEtcMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithFullVotingRightsOtherMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesLessThanOneUnitMember | － | |
| Treasury shares etc (text) | FilingDateInstant | Text · Plus | |
| Name of shareholder treasury shares etc | CurrentQuarterInstant_Row1Member | Original text (Japanese)H.U.グループホールディングス株式会社 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |